Home About Clinicians Patients Investors Careers Media Contact Media > News Monday 11 October 2021 Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres® Y-90 resin microspheres in China WOBURN, Mass. (October 11, 2021) – Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced today that the first procedure of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in China was successfully performed for a patient with hepatocellular carcinoma (HCC) on Sept. 28, 2021. The milestone was reached with the support of Sirtex shareholder China Grand Pharmaceutical and Healthcare Holdings Limited. Read more Download PDF Tuesday 08 June 2021 Sirtex Medical provides donations to Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital in support of the Artzi Lab, as part of Sirtex’s corporate citizenship strategy to support research and innovation. WOBURN, Mass. (June 8, 2021) –– Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, has provided grants to Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital for the advancement of cancer treatment, to be shared with the independent Artzi Lab. Read more Download PDF Tuesday 19 January 2021 Sirtex Medical announces collaboration update with OncoSec Medical WOBURN, Mass. (January 19, 2021) –– Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ:ONCS) relating to OncoSec’s lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system Read more Download PDF Wednesday 09 December 2020 Sirtex Medical announces strategic investment in BlackSwan Vascular, Inc. WOBURN, Mass. (December 9, 2020) –– Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, announced a strategic investment in BlackSwan Vascular, Inc. (BlackSwan), a Bay Area based private company developing groundbreaking therapies in endovascular embolization. Read more Download PDF Wednesday 25 November 2020 Sirtex Medical and China Grand Pharmaceutical announce SIR-Spheres® Y-90 resin microspheres milestone WOBURN, Mass. (November 25, 2020) -- Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex with the support of its shareholder, China Grand Pharmaceutical and Healthcare Holdings Limited (CGP), has been notified of the acceptance by the National Medical Products Administration (NMPA) of the People’s Republic of China of its new drug application (NDA) of SIR-Spheres® Y-90 resin microspheres. Read more Download PDF Tuesday 06 October 2020 Sirtex Medical appoints Francis Jannot as Executive Vice President of International Sales WOBURN, Mass. (October 6, 2020) –– Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Mr. Francis Jannot as Executive Vice President of International Sales. Read more Download PDF Tuesday 08 September 2020 Sirtex Medical announces strategic investment in Nanospectra Biosciences WOBURN, Mass. (September 8, 2020) –– Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced a lead and strategic investment in Nanospectra Biosciences, Inc. (Nanospectra), a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, as part of Nanospectra’s Series B-1 round of financing. Read more Download PDF Thursday 27 August 2020 Sirtex Medical and China Grand Pharmaceutical announce landmark drug registration milestone WOBURN, Mass. (August 27, 2020) –– Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today that Sirtex and its shareholders, China Grand Pharmaceutical and Healthcare Holdings Limited (CGP), have been issued a "Notice of Drug Clinical Trial Approval" by the National Medical Products Administration (NMPA) of the People’s Republic of China. Read more Download PDF Monday 17 August 2020 Sirtex Medical announces partnership with Magle Chemoswed WOBURN, Mass. (August 17, 2020) –– Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced a collaboration with Magle Chemoswed, a Malmö, Sweden-based contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. Read more Download PDF Wednesday 03 June 2020 Sirtex Medical appoints Dr. Mark A. Turco as Global Chief Medical Officer and EVP of Research & Development WOBURN, Mass. (June 3, 2020) –– Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced the appointment of Dr. Mark A. Turco, FACC, as Global Chief Medical Officer and EVP of Research & Development, effective June 1, 2020. Read more Download PDF Wednesday 12 February 2020 Sirtex Medical announces collaboration with MIM Software Inc. WOBURN, Mass. (February 12, 2020) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced a collaboration with MIM Software Inc., a leading global provider of practical imaging solutions in the fields of radiation oncology, radiology, nuclear medicine, neuroimaging and cardiac imaging. Under the terms of the agreement, Sirtex’s specialized sales teams in the United States, Europe and other key global markets will offer MIM SurePlanTM LiverY90 software alongside the company’s SIR-Spheres® Y-90 resin microspheres to improve treatment precision for patients with hepatic tumors. Read more Download PDF Languages: Monday 10 February 2020 Sirtex Medical Announces Closing of Strategic Transaction with OncoSec Medical, Inc. WOBURN, Mass. (February 10, 2020) – Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, today announced that the shareholders of OncoSec Medical, Inc. (“OncoSec”) have approved, and the parties have closed, the strategic investment by and partnership with Sirtex and Grand Decade Developments Limited, a wholly owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (“CGP”). The signing of the strategic transaction was previously announced on October 10, 2019. Read more Download PDF Wednesday 16 October 2019 Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer WOBURN, Mass. (October 16, 2019) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced the appointment of Kevin R. Smith as Chief Executive Officer of Sirtex Medical Pty Ltd. Sirtex is a global healthcare business with offices and manufacturing facilities in the U.S., Australia, Germany and Singapore. Read more Download PDF Thursday 10 October 2019 Sirtex Medical and China Grand Pharmaceutical announce a strategic transaction with OncoSec Medical Incorporated PENNINGTON, N.J., Oct. 10, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (Nasdaq:ONCS), a late-stage intratumoral cancer immunotherapy company, today announced it entered into a strategic transaction with Grand Decade Developments Limited (Grand Decade), a direct, wholly-owned subsidiary of China Grand Pharmaceutical and Healthcare Holdings Limited (CGP) (HKG:512), and its affiliate, Sirtex Medical US Holdings, Inc. (Sirtex). Read more Download PDF Monday 24 June 2019 Sirtex Medical reaches milestone 100,000th patient dose delivery of SIR-Spheres® Y-90 resin microspheres WOBURN, Mass. (June 20, 2019) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres® Y-90 resin microspheres, a treatment for patients with liver cancer.* More than 1,000 healthcare providers and hospital systems across the globe offer this treatment. Read more Download PDF Languages: Tuesday 11 October 2016 New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA) Sirtex Medical Limited (ASX:SRX) announced today that the European Society of Medical Oncology (ESMO) has indicated the use of SIRT using yttrium-90 (Y-90) microspheres as an option for the treatment of intrahepatic cholangiocarcinoma (iCCA), a form of primary liver cancer that starts in the bile duct, the branching network of thin tubes that deliver fat-digesting bile from the liver to the small intestine. Read more Download PDF Languages: Thursday 29 January 2015 FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC) Read more Download PDF Languages: Monday 08 September 2014 Sirtex Medical Inc. Expands Business into Brazil, Experiences Record Growth First SIR-Spheres® microspheres treatment at Hospital Sirio-Libanes in Sao Paulo, Brazil Read more Download PDF Saturday 13 April 2013 Sirtex Completes Patient Recruitment for SIRFLOX Study Evaluating SIR-Spheres® Microspheres as First-Line Treatment for Colorectal Liver Metastases World’s Largest Interventional Oncology Study with More Than 500 Patients Enrolled Read more Download PDF Tuesday 11 December 2012 Sirtex Medical Limited Launches New Global Website for SIR-Spheres® microspheres – a form of Selective Internal Radiation Therapy (SIRT) for Liver Tumours www.sirtex.com informs doctors, patients and investors about the world’s most widely used and widely studied form of SIRT for all cancers in the liver Read more Download PDF Wednesday 15 August 2012 Sirtex Medical Inc. Expands U.S. Operations to Accommodate Increased Demand for SIR-Spheres® Microspheres Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today expansion of U.S. operations with the placement of additional sales, marketing, and functional support staff in Massachusetts and across the country. Read more Download PDF Thursday 07 July 2011 Six Year Study Confirms Sirtex´s Liver Cancer Therapy Safe and Effective Download PDF Thursday 24 June 2010 Sirtex Invests in New Major Asia Pacific Study to Expand Clinical Use Download PDF Tuesday 08 June 2010 SIRTEX Reports Positive Results From Asian Clinical Trial Combination of SIR-Spheres® Microspheres and Chemotherapy Shows Improved Survival for Inoperable Hepatocellular Carcinoma (HCC) Liver Cancer Patients. Median overall survival of 11.75 months in a HCC patient population with limited treatment options Read more Download PDF Monday 01 March 2010 New UK Trial With Oxford University To Test New Bowel Cancer Therapy Oncology treatment company Sirtex Medical Limited (ASX: SRX) today announced the start of a new trial to see if chemotherapy used with SIR-Spheres® microspheres targeted radiation therapy is more effective than just chemotherapy in patients with bowel cancer that has spread to the liver. Read more Download PDF Thursday 11 February 2010 Sirtex Joins Bayer Healthcare in Major European Liver Cancer Trial Download PDF Tuesday 01 July 2008 Fourth Annual Symposium on Liver-Directed Microsphere Therapy Raises Awareness of the Latest Advances for Treating Metastatic Liver Tumors Clinical Symposium Featured New Data and Research on the use of Sirtex’s SIR-Spheres® Microspheres Read more Download PDF Friday 13 June 2008 SIR-Spheres® Microspheres Featured at the 2008 Society of Nuclear Medicine Annual Meeting Sirtex, a leading developer of targeted and innovative cancer therapies, will exhibit its SIR-Spheres microspheres technology at the 2008 Society of Nuclear Medicine (SNM) Annual Meeting. The meeting, to be held June 14-18 at the Convention Center in New Orleans, La., is considered the premier educational and scientific event in the nuclear medicine community. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved microsphere therapy for advanced colorectal cancer that has metastasized to the liver. Read more Download PDF Thursday 24 April 2008 Sirtex Supports the Fourth Annual Clinical Symposium on Liver-Directed Microsphere Therapy Dedicated to Advancing Treatments for Patients with Inoperable Metastatic Liver Cancer Meeting to Highlight Latest Clinical Advances with the Use of Yttrium-90 Microsphere Therapy to Control one of the Deadliest Forms of Cancer Read more Download PDF Monday 31 March 2008 Sirtex Medical receives US FDA Approval to Proceed with FAST Clinical Trial Update on Clinical Trial Evaluating SIR-Spheres Microspheres with Bevacizumab and Chemotherapy as a First-Line Treatment for Unresectable Metastatic Colorectal Cancer Read more Download PDF Wednesday 03 October 2007 Sirtex Medical Signs Agreements with Peter MacCallum Cancer Centre to Develop and Market Innovative Cancer Treatment Technology Download PDF Wednesday 18 April 2007 Sirtex Medical Announces Expansion of its R&D Programs to Develop new Oncology Therapies and Product Enhancements Download PDF Tuesday 27 March 2007 Sirtex to Participate in the 2007 American Society of Clinical Oncology Annual Conference New Data Regarding Repeat Treatments of SIR-Spheres® Microspheres in Patients with Advanced Liver Tumors to be Included at Annual Meeting Read more Download PDF News Corporate News Product News External Research News External Resource News - Media Materials + Email Alerts Events Media Contact Who we are Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. What are SIR-Spheres® Y-90 resin microspheres? SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. To view the Technical Bulletin regarding our indication, click here. Contact or follow us Contact Us SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Terms of Use | Privacy Information W9-E-0214 By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage. Yes Go to Homepage SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. Click here to view our Technical Bulletin. Ok